Pharma: Page 14
-
Danielle Ternes/BioPharma Dive
JPM25: Deals, Summit’s bravado and gene therapy headwinds
Drug executives talked M&A and the incoming administration, but also weighed the outlook for cell and gene therapy developers after a difficult year.
By Ben Fidler , Delilah Alvarado , Gwendolyn Wu • Updated Jan. 14, 2025 -
Mario Tama via Getty Images
Brain drug revivalJ&J to buy psychiatric drug developer Intra-Cellular for $14.6B
Intra-Cellular has had success selling Caplyta, a brain-rebalancing drug that's approved to treat schizophrenia and bipolar depression.
By Ned Pagliarulo , Jacob Bell • Updated Jan. 13, 2025 -
Explore the Trendline➔
National Institute on Aging. (2017). "Beta-Amyloid Plaques and Tau in the Brain" [Image]. Retrieved from Flickr.
TrendlineAlzheimer's disease
Many companies hope to follow in the footsteps of Biogen, Eisai and Eli Lilly by developing new therapies for the debilitating disease, which affects tens of millions of people and costs healthcare systems hundreds of billions of dollars each year.
By BioPharma Dive staff -
Permission granted by Almac Clinical Services
Sponsored by Almac Clinical ServicesLack of regulatory harmonization and other challenges facing clinical services organizations in the APAC market
How clinical services organizations are overcoming challenges in the APAC market.
Jan. 13, 2025 -
Getty Images
Pfizer’s PD-1 drug succeeds; AbbVie writes down $3.5B in Cerevel assets
Sasanlimab, a subcutaneous immunotherapy developed by Pfizer, could help treat bladder cancer. Elsewhere, Royalty Pharma moved to simplify its corporate structure and Biogen made another hire.
By BioPharma Dive staff • Jan. 10, 2025 -
Scott Olson/Getty Images via Getty Images
5 questions facing pharma in 2025
Political and economic uncertainty hangs over the industry, while major bets on metabolic and immune disease drug research are set to play out.
By Ned Pagliarulo , Jonathan Gardner , Delilah Alvarado • Jan. 9, 2025 -
Sean Gallup via Getty Images
Bayer says menopause drug succeeds in breast cancer study
The results suggest Bayer’s elinzanetant may help a broader group of women with vasomotor symptoms, which are associated with menopause as well as a common breast cancer therapy.
By Delilah Alvarado • Jan. 9, 2025 -
Sarah Silbiger via Getty Images
VaccinesFDA adds warning to RSV shots from GSK, Pfizer
The regulator is requiring labeling that warns of Guillan-Barré syndrome, although it said data don’t prove a causal link and affirmed the shots’ benefit outweighs their risks.
By Delilah Alvarado • Jan. 8, 2025 -
Getty Images
Tenvie raises $200M for brain drug R&D; Sana spikes on single patient’s results
The Arch-backed startup begins life with several assets acquired from Denali Therapeutics. Elsewhere, Jasper got a negative reaction to data for its hives drug and Stoke finalized Phase 3 trial plans.
By BioPharma Dive staff • Jan. 8, 2025 -
Mi-Tah / Shutterstock
Sponsored by Esperion TherapeuticsAn evolution in leadership and vision for this pharma company
Esperion CEO Sheldon Koenig reflects on personal challenges and advancing innovative heart therapies.
Jan. 6, 2025 -
Getty Images
Pfizer exits Sangamo pact; Roche, Ideaya strike ADC deals
Sangamo shares fell on Pfizer’s decision to hand back rights to a hemophilia gene therapy. Elsewhere, Novartis got long-awaited data and BioNTech settled with the NIH.
By BioPharma Dive staff • Jan. 2, 2025 -
Getty Images
Ionis gets a milestone approval; Another top FDA official to step down
The clearance of Tryngolza gives Ionis its first wholly-owned, marketed medicine. Elsewhere, Robert Temple became the latest FDA leader to leave the agency, and two biotechs cut research deals.
By BioPharma Dive staff • Dec. 20, 2024 -
Courtesy of Novo Nordisk
Novo’s next-gen obesity drug misses expectations in closely watched trial
Novo shares lost nearly a fifth of their value after an experimental combination treatment called cagrisema fell short of the bar set by executives.
By Jonathan Gardner • Updated Dec. 20, 2024 -
Getty Images
Regeneron says study data support big bet on new blood thinners
The company is planning a “broad Phase 3 program” for two anticoagulants after they outperformed marketed medicines in a pair of mid-stage trials.
By Jonathan Gardner • Dec. 19, 2024 -
Permission granted by Novartis
Novartis shutters MorphoSys sites, lays off staff
While the pharma is still developing a MorphoSys drug acquired in its $2.9 billion deal for the biotech, it is closing down sites in the U.S. and Germany.
By Delilah Alvarado • Dec. 19, 2024 -
Kena Betancur via Getty Images
Merck moves into obesity with deal for Hansoh’s GLP-1 pill
News of Merck’s licensing of Hansoh’s preclinical medicine pressured shares in Viking and other obesity drug developers seen as likely buyout targets.
By Jonathan Gardner • Dec. 18, 2024 -
Getty Images
Tessera gets sickle cell funding; Corvus shares slide on eczema data
The Bill & Melinda Gates Foundation will invest up to $50 million in Tessera’s in vivo sickle cell therapy. Elsewhere, Cara agreed to a reverse merger and J&J had a drug application rejected.
By BioPharma Dive staff • Dec. 18, 2024 -
Getty Images
Pfizer predicts stability, to Wall Street’s relief
The company forecast revenue next year will grow slightly versus this year, when excluding certain factors. “The uncertainty caused by COVID [is] mostly resolved,” its CFO said.
By Ned Pagliarulo • Dec. 17, 2024 -
Getty Images
Sanofi, Teva say study results show gut disease drug could be ‘best in class’
Phase 2 results in inflammatory bowel disease hinted the therapy could be more potent than similar medicines from Merck and Roche, each of which were acquired in multibillion-dollar deals.
By Ben Fidler • Dec. 17, 2024 -
Getty Images
Novo builds up manufacturing; Pepgen Duchenne trial put on hold
Novo Nordisk is investing more than $1 billion in a new production facility in Denmark. Elsewhere, drugs from Neurocrine Biosciences, Checkpoint and Galderma won new FDA approvals.
By BioPharma Dive staff • Dec. 16, 2024 -
Getty Images
Merck calls quits on two immunotherapies for cancer
The company is scrapping two drugs aimed at targets called TIGIT and LAG-3, both of which were in the middle of Phase 3 testing.
By Jonathan Gardner • Dec. 16, 2024 -
Getty Images
Padlock investors sue Bristol Myers; Dietmar Berger is Gilead’s new CMO
Padlock Therapeutics investors accused Bristol Myers of avoiding making milestone payments promised under a 2016 deal. Elsewhere, Gilead CEO Daniel O’Day hired Berger away from Sanofi.
By BioPharma Dive staff • Dec. 13, 2024 -
Getty Images
With new data, Lilly sets pace for next wave of breast cancer drugs
While other big pharmas have faltered, Lilly made headway in a Phase 3 trial that could provide a treatment option to replace fulvestrant.
By Jonathan Gardner • Updated Dec. 11, 2024 -
Getty Images
BenevolentAI restructures; Lilly preps $15B buyback program
The drug discovery specialist is laying off staff in a pivot that could take it private. Elsewhere, AbbVie reported a second Parkinson’s study success and Biogen hired a new Wall Street whisperer.
By BioPharma Dive staff • Updated Dec. 17, 2024 -
kirisa99/istockphoto.com
Sponsored by EvaluateWhat’s behind pharma’s growth boost?
Pharma is forecast for a 7.7% growth rate to 2030. What’s driving it? (hint: it’s not just obesity).
Dec. 9, 2024 -
Permission granted by Almac Clinical Services
Sponsored by Almac Clinical Services
Clinical services organizations are critical to the future of pharma in the APAC market
As APAC contract manufacturing grows, pharma companies turn to outsourcing for cost-effective solutions.
Dec. 9, 2024
Previous
